Company Profile
Suzhou Venmed Technology Co., Ltd. (doing business as Tianhong Shengjie) is a China-based manufacturer of venous and peripheral vascular interventional devices, headquartered in Suzhou, Jiangsu, China. Founded on March 25, 2016 by Chairman Wang Yonggang, the company operates as an independent private entity with 114 employees, serving domestic and global peripheral vascular markets through a comprehensive product ecosystem covering venous, arterial, and tumor embolization therapies.
Core Products ＆ Technologies
Venous Intervention
• Venastent® Iliac Vein Stent System: Domestic-first iliac vein stent approved via RCT, featuring large-flare design, segmented open-closed loop structure, triple-row radiopaque markers, and thin-wall construction for IVCS and DVT
• Peripheral Balloon Catheters: PTA balloons including high-pressure and constrained-type (V-Hive™) designs for venous and arterial dilatation; diameters up to 18mm for iliac-femoral applications
• Thrombolytic Catheters: Devices for catheter-directed thrombolysis in deep vein thrombosis treatment
Peripheral Arterial ＆ Access
• Peripheral Guidewires: Hydrophilic-coated guidewires for navigation in peripheral vasculature during diagnostic and interventional procedures
• Introducer Sheaths: Vascular access sheaths for establishing percutaneous entry pathways
• Distal Protection Devices: Nitinol filter-based embolic protection with gradient pore design (50-300μm) for efficient capture and safe delivery
Other Vascular Solutions
• Intravascular Foreign Body Retrieval System: Snare and catheter system for retrieving dislodged stents, fractured catheters, and guidewires (excluding neurovascular)
• Great Saphenous Vein Stripping Catheter: Device for varicose vein removal
• Balloon Inflation Devices: Pressure pumps for precise balloon inflation during angioplasty
Market Position ＆ Certifications
Suzhou Venmed holds a leading domestic position in China's venous interventional device market, ranking first among domestic brands for iliac vein stents and competing with Cook Medical (Zilver Vena). Key strengths include:
• 10 years of Chinese engineering heritage in venous intervention
• RCT-validated portfolio: Venastent backed by a 256-patient multicenter study (19 hospitals, 2018-2021) demonstrating 100% 12-month patency in the experimental group and comparable safety to imported controls
• Regulatory compliance: Dozens of NMPA product registrations including Class III approvals for stents, balloons, and access devices; ISO 13485:2016 certified
• Full venous coverage: 100% coverage of peripheral venous disease devices with expansion into arterial and embolization segments
• Commercial scale: Hundreds of distributors covering 1,000+ hospitals across China; volume leader in domestic iliac stent procurement
Corporate Timeline
2016 — Founded in Suzhou, Jiangsu, China, focusing on venous interventional therapy
2018 — Venastent entered the NMPA Innovation Medical Device Special Review Program (green channel)
2021 — Completed approximately RMB100M Series B financing led by Wuxi Guolian, with participation from Hetang Ventures, Ziniu Fund, and Ningbo Kangtuo
2022 — Venastent® received first-in-class domestic NMPA approval for iliac vein stent (April); enabled new 5,000sqm manufacturing facility (September); completed tens of millions RMB B+ financing led by Qiaojing Capital and Zhuopu Capital (October)
2025 — Selected in the National Centralized Procurement (Volume-Based Purchasing) for peripheral vascular stents (July)
2026 — Received three Class III NMPA approvals in January (peripheral balloon, distal protection device, V-Hive™ constrained balloon); completed tens of millions RMB equity financing led by Chuangjing Capital (May)
Target Markets ＆ Applications
• Iliac Vein Compression Syndrome (IVCS): Venastent stenting for May-Thurner syndrome and venous stenosis
• Deep Vein Thrombosis (DVT): Thrombolytic catheters and venous stenting for acute and chronic DVT
• Peripheral Artery Disease (PAD): PTA balloons and guidewires for iliac, femoral, popliteal, and tibial artery lesions
• Embolic Protection: Distal protection devices for preventing distal embolization during venous and arterial interventions
• Varicose Vein Treatment: Stripping catheters for great saphenous vein removal
Contact Information
Global Headquarters
Address: Room 202, 501, 502, Building 7, No. 188 Fuchunjiang Road, Suzhou High-tech Zone, Suzhou, Jiangsu, China
Telephone: 0512-62910800
Email: lindalin@venmed.com
Corporate Status
Entity Type: Independent Private Company (No Parent Company)
Stock: Not Publicly Traded
Website: Not publicly available
